The affected lots, No. 6120341 and No. 6120420, were distributed between Dec. 6, 2018, and Feb. 20, 2019.
“Products containing glass particulate should not be administered intravenously due to the potential for life-threatening consequences,” the drugmaker said in its recall notice.
To date, Fresenius said it hasn’t received reports of adverse events related to the glass particles.
More articles on pharmacy:
Walmart cutting some pharmacy jobs
UPMC acquires community pharmacy in Pittsburgh
Oklahoma judge approves Teva’s $85M opioid settlement
